Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

NANot yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Atrial Fibrillation (AF)
Interventions
DRUG

Dapagliflozin Treatment Group

"This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day)."

All Listed Sponsors
collaborator

Hefei Binhu Hospital

OTHER

collaborator

The First People's Hospital of Hefei

OTHER

collaborator

Second People's Hospital of Hefei City

OTHER

collaborator

The Second People's Hospital of Anhui Province

OTHER

lead

Xu Liu

OTHER

NCT06740786 - Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation | Biotech Hunter | Biotech Hunter